{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:24:18Z","timestamp":1778570658897,"version":"3.51.4"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Dyslipidaemias are a major risk factor for cardiovascular disease (CVD); in particular, high levels of low-density lipoprotein cholesterol (LDL-C) have been associated to a higher cardiovascular risk. Reducing LDL-C levels decreases the risk of coronary heart disease (CHD), and the greater the LDL-C reduction, the greater the decrease in cardiovascular risk. Although statins represent the first line lipid-lowering therapy, many patients do not reach the recommended goals or exhibit adverse side effects leading to therapy discontinuation; in addition, a significant percentage of statin-treated patients continue to experience cardiovascular events even in the presence of well controlled LDL-C levels, because of alterations in other lipid\/lipoprotein classes, including triglycerides and high-density lipoprotein cholesterol.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>These conditions require further therapeutic interventions to achieve the recommended lipid goals. Several drugs have been developed to address these needs. Recent studies have shown that the association of ezetimibe with rosuvastatin or atorvastatin results in a better hypolipidaemic effect; in addition to this, PCSK9 inhibitors significantly reduce LDL-C levels and cardiovascular events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>For patients who are intolerant to statins or not able to reach the recommended LDL-C levels, despite maximal tolerated dose of statin, or exhibiting additional lipid alterations, several drugs are available that can be used either in monotherapy or on top of the maximally tolerated dose of statins.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000459","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T23:51:19Z","timestamp":1505346679000},"page":"458-464","source":"Crossref","is-referenced-by-count":2,"title":["Strategies for the use of nonstatin therapies"],"prefix":"10.1097","volume":"28","author":[{"given":"Angela","family":"Pirillo","sequence":"first","affiliation":[{"name":"Center for the Study of Atherosclerosis, E. Bassini Hospital, Cinisello Balsamo"},{"name":"IRCCS Multimedica Hospital, Sesto San Giovanni"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe D.","family":"Norata","sequence":"additional","affiliation":[{"name":"Center for the Study of Atherosclerosis, E. Bassini Hospital, Cinisello Balsamo"},{"name":"Department of Pharmacological and Biomolecular Sciences, Universit\u00e0 degli Studi di Milano, Milan, Italy"},{"name":"School of Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[{"name":"IRCCS Multimedica Hospital, Sesto San Giovanni"},{"name":"Department of Pharmacological and Biomolecular Sciences, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170\u200a000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90\u200a056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174\u200a000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4093\/dmj.2015.39.2.87","article-title":"New drugs for treating dyslipidemia: beyond statins","volume":"39","author":"Ahn","year":"2015","journal-title":"Diabetes Metab J"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2840-13-26","article-title":"Residual macrovascular risk in 2013: what have we learned?","volume":"13","author":"Fruchart","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2337\/db16-0046","article-title":"Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol","volume":"65","author":"Xiao","year":"2016","journal-title":"Diabetes"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jama.298.3.336","article-title":"Triglycerides and risk for coronary heart disease","volume":"298","author":"McBride","year":"2007","journal-title":"JAMA"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/HCO.0b013e32832c1284","article-title":"Triglycerides as vascular risk factors: new epidemiologic insights","volume":"24","author":"Kannel","year":"2009","journal-title":"Curr Opin Cardiol"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1161\/ATVBAHA.111.226100","article-title":"Triglycerides and heart disease: still a hypothesis?","volume":"31","author":"Goldberg","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Jorgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","article-title":"Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER)","volume":"105","author":"Nicholls","year":"2010","journal-title":"Am J Cardiol"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.amjcard.2016.02.011","article-title":"A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia","volume":"117","author":"Karlson","year":"2016","journal-title":"Am J Cardiol"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1194\/jlr.P002816","article-title":"Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database","volume":"51","author":"Barter","year":"2010","journal-title":"J Lipid Res"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10557-008-6113-z","article-title":"Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit","volume":"22","author":"McTaggart","year":"2008","journal-title":"Cardiovasc Drugs Ther"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.clinthera.2010.02.004","article-title":"Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy","volume":"32","author":"Corrao","year":"2010","journal-title":"Clin Ther"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","article-title":"Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its nonrandomised nonblind extension phase","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.amjcard.2005.11.039","article-title":"Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia","volume":"97","author":"Bays","year":"2006","journal-title":"Am J Cardiol"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40256-013-0037-0","article-title":"Role of colesevelam in combination lipid-lowering therapy","volume":"13","author":"Jones","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2174\/0929867323666160229114111","article-title":"Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases","volume":"23","author":"Pirillo","year":"2016","journal-title":"Curr Med Chem"},{"key":"R31-20230917","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1056\/NEJMoa1405386","article-title":"Inactivating mutations in NPC1L1 and protection from coronary heart disease","volume":"371","author":"Stitziel","year":"2014","journal-title":"N Engl J Med"},{"key":"R32-20230917","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21\u200a000 patients from 27 clinical trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2710.2008.01004.x","article-title":"Efficacy and safety of ezetimibe\/simvastatin association on nondiabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment","volume":"34","author":"Derosa","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N Engl J Med"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40256-016-0205-0","article-title":"Defining the place of ezetimibe\/atorvastatin in the management of hyperlipidemia","volume":"17","author":"Ferreira","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clinthera.2016.11.014","article-title":"Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk","volume":"39","author":"Yang","year":"2017","journal-title":"Clin Ther"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12944-017-0508-4","article-title":"Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects","volume":"16","author":"Sakamoto","year":"2017","journal-title":"Lipids Health Dis"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/1755-5922.12213","article-title":"Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)","volume":"34","author":"Kim","year":"2016","journal-title":"Cardiovasc Ther"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-pharmtox-011613-140025","article-title":"Targeting PCSK9 for hypercholesterolemia","volume":"54","author":"Norata","year":"2014","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R43-20230917","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"R44-20230917","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R45-20230917","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 Randomized Clinical Trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"R46-20230917","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"R47-20230917","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R48-20230917","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","article-title":"2016\u200aESC\/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"key":"R49-20230917","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART Registry follow-up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R50-20230917","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.atherosclerosis.2006.10.036","article-title":"Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients","volume":"194","author":"Pisciotta","year":"2007","journal-title":"Atherosclerosis"},{"key":"R51-20230917","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"key":"R52-20230917","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"R53-20230917","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"R54-20230917","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160\u200amg\/dl or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"R55-20230917","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","article-title":"Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"R56-20230917","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","article-title":"Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins - ODYSSEY JAPAN Randomized Controlled Trial","volume":"80","author":"Teramoto","year":"2016","journal-title":"Circ J"},{"key":"R57-20230917","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","article-title":"Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial","volume":"37","author":"Moriarty","year":"2016","journal-title":"Eur Heart J"},{"key":"R58-20230917","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","article-title":"Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"R59-20230917","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"R60-20230917","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jacl.2016.12.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia","volume":"11","author":"Kastelein","year":"2017","journal-title":"J Clin Lipidol"},{"key":"R61-20230917","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"R62-20230917","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV Randomized Clinical Trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"R63-20230917","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"R64-20230917","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"R65-20230917","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jacl.2016.03.008","article-title":"Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia","volume":"10","author":"Maki","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R66-20230917","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.001800","article-title":"Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis","volume":"1","author":"Jones","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"R67-20230917","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ahj.2011.03.023","article-title":"Institutional, provider, and patient correlates of low-density lipoprotein and nonhigh-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines","volume":"161","author":"Virani","year":"2011","journal-title":"Am Heart J"},{"key":"R68-20230917","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117\u200a411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ"},{"key":"R69-20230917","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2015.04.228","article-title":"Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: a meta-analysis of randomized controlled trials","volume":"191","author":"Ip","year":"2015","journal-title":"Int J Cardiol"},{"key":"R70-20230917","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"key":"R71-20230917","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"R72-20230917","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"R73-20230917","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.ijcard.2013.06.040","article-title":"Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia","volume":"170","author":"Pirillo","year":"2013","journal-title":"Int J Cardiol"},{"key":"R74-20230917","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"R75-20230917","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1161\/01.CIR.0000014682.14181.F2","article-title":"Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto Miocardico (GISSI)-Prevenzione","volume":"105","author":"Marchioli","year":"2002","journal-title":"Circulation"},{"key":"R76-20230917","first-page":"826","article-title":"A Comparative overview of prescription omega-3 fatty acid products","volume":"40","author":"Ito","year":"2015","journal-title":"P & T"},{"key":"R77-20230917","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCOUTCOMES.112.966168","article-title":"Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis","volume":"5","author":"Kotwal","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201712000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:02:56Z","timestamp":1694937776000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201712000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000459","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}